



Date: 15/05/2026

To,
BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To,
National Stock Exchange of India
Limited
Listing Department "Exchange Plaza,"
C-1, Block - G, Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Scrip Code: 544666

Dear Sir/Madam

Subject: Monitoring Agency Report issued by Brickwork Ratings India Private Limited for the utilization and application of funds raised through the Initial Public Offer (IPO) of Gujarat Kidney Super Speciality Limited ("the company") for the quarter ended March 31, 2026

Pursuant to Regulation 32(6) of the SEBI Listing Regulations read with Regulation 41(4) of the SEBI ICDR Regulations, we have enclosed herewith the Monitoring Agency Report issued by Brickwork Ratings India Private Limited, Monitoring Agency, for the quarter ended March 31, 2026, in respect of the utilization and application of funds raised through the IPO.

This information shall also be made available on the Company's website at: www.gujaratsuperspecialityhospital.com under announcement/intimation to stock exchange tab.

You are requested to take the above information on record.

Thanking you.

For Gujarat Kidney Super Speciality Limited

Vishakha Mahesh Phadke

Company Secretary and Compliance Officer
Membership No. A37675

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited

CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

**Monitoring Agency Report for
Gujarat Kidney and Super
Speciality Limited
for the quarter ended
March 31, 2026**

No. BWR/2026-27/IPM/GKASSL/02
May 15, 2026

To
Bhavikaben Mitesh Patel
Chief Financial Officer
Gujarat Kidney and Super Speciality Limited
Plot No. 1, City Sarve No. 1537/A,
Jetalpur Road, Gokak Mill Compound, Alkapuri,
Vadodara- 390020, Gujarat

Dear Sir,

**Second Monitoring Agency Report for the quarter ended March 31, 2026 - in relation to the
Fresh Issue of Equity Shares of Gujarat Kidney and Super Speciality Limited (“the
Company”)**

Pursuant to Regulation 41 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Engagement Letter dated August 19, 2025, Brickwork Ratings (BWR) has prepared the Second Monitoring Agency Report, as per Schedule XI of the SEBI ICDR Regulations towards utilisation of proceeds of funds raised, for the quarter ended March 31, 2026.

The funds raised by the Company were through Fresh Issue of Equity Shares aggregating to Rs. 250.80 Crore of the Company.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended March 31, 2026, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated August 20, 2025.

Request you to kindly take the same on records.

Thanking you,
Yours Faithfully,

NIRAJ KUMAR
RATHI

Digitally signed by
NIRAJ KUMAR RATHI
Date: 2026.05.15
15:42:24 +05'30'

Mr Niraj Kumar Rathi
Senior Director, Ratings - Brickwork Ratings

Report of the Monitoring Agency (MA)**Name of the issuer:** Gujarat Kidney and Super Speciality Limited**For quarter ended:** March 31, 2026**Name of the Monitoring Agency:** Brickworks Ratings India Private Limited

(a) Deviation from the objects: No

(b) Range of Deviation: Not Applicable

Declaration:

We declare that this report is based on the format prescribed by the SEBI (ICDR) Regulations, 2018, we further declare that this report provides a true and fair view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable.

We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

The MA does not perform an audit and undertakes no independent verification of any information/certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have a credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

NIRAJ KUMAR RATHI
Digitally signed by
NIRAJ KUMAR RATHI
Date: 2026.05.15
15:42:39 +05'30'

Signature:**Name of the Authorized Signatory: Mr Niraj Kumar Rathi****Designation of Authorized Person/Signing Authority: Senior Director, Ratings - Brickwork Ratings**

1) Issuer Details:

Name of the issuer:	Gujarat Kidney and Super Speciality Limited
Names of the promoter:	Pragnesh Yashwantsinh Bharpoda, Bhartiben Pragnesh Bharpoda, Yashwantsingh Motisinh Bharpoda & Anitaben Yashwantsinh Bharpoda
Industry / sector to which it belongs:	Hospitals

2) Issue Details:

Issue period:	For anchor investors – 19 December 2025 For others - 22 December 2025 to 24 December 2025
Type of issue (public/ rights):	Fresh Issue of Equity shares
Type of specified securities:	Equity Shares
IPO Grading, if any:	Not Applicable
Issue size (in ₹ Crore):	250.80

Particulars	Total Number of Securities	Price (₹)	Value as per Offer Document (₹ Crore)	Amount Received (₹ Crore)
Equity Shares-Fresh Issue	2,20,00,000	114	250.80	250.80
Total	2,20,00,000	114	250.80	250.80

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Bank Statements, Invoices, Company's Letter, CA Certificate	Nil	Nil
Whether shareholder approval has been obtained in case of material deviations [#] from expenditures disclosed in the Offer Document?	Not Applicable	Nil	Nil	Nil
Whether the means of finance for the disclosed objects of the issue has changed?	No	Nil	Nil	Nil
Is there any major deviation observed over the earlier monitoring agency reports?	Not Applicable	Nil	Nil	Nil
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Company's letter	Nil	Nil
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not Applicable	Nil	Nil	Nil
Are there any favorable events improving the viability of these object(s)?	No	Company's letter	Nil	Nil
Are there any unfavorable events affecting the viability of the object(s)?	No	Company's letter	Nil	Nil
Is there any other relevant information that may materially affect the decision making of the investors?	No	Not Applicable	Nil	Nil

Note: CA Certificate from Y.M. Shah & Co. Chartered Accountant

Above details verified by Company Statement dated May 14, 2026.

[#]Where material deviation may be defined to mean:

(a) Deviation in the objects or purposes for which the funds have been raised

(b) Deviation in the amount of funds actually utilised by more than 10% of the amount projected in the offer documents.

4) Details of object(s) to be monitored:
i. Cost of object(s):

Sr. No.	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original Cost (as per the Offer Document) (₹ Crore)	Revised Cost (₹ Crore)	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1.	Proposed acquisition of Parekhs Hospital at Ahmedabad	Bank Statements, Company Letter, CA Certificate	77.00	NA	Nil	Nil	Nil	Nil
2	Part-payment of purchase consideration for the already acquired "Ashwini Medical Centre"	Bank Statements, Company Letter, CA Certificate	12.40	NA	Nil	Nil	Nil	Nil
3.	Acquisition of additional shareholding in our subsidiary namely "Harmony Medicare Private Limited" at Bharuch	Bank Statements, Company Letter, CA Certificate	10.78	NA	Nil	Nil	Nil	Nil
4.	Funding of capital expenditure requirements of our Company towards setting up of a new hospital in Vadodara	Bank Statements, Company Letter, CA Certificate	30.10	NA	Nil	Nil	Nil	Nil
5.	Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital at Vadodara location	Bank Statements, Company Letter, CA Certificate	6.83	NA	Nil	Nil	Nil	Nil
6.	Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company	Bank Statements, Company Letter, CA Certificate	1.20	NA	Nil	Nil	Nil	Nil
7.	Funding inorganic growth through unidentified acquisitions and General Corporate Purposes	Bank Statements, Company Letter, CA Certificate	87.44	NA	Nil	Nil	Nil	Nil
8.	Issue Expenses	Bank Statements, Company Letter, CA Certificate	25.05	NA	Nil	Nil	Nil	Nil
9.	Any other purpose approved by board	NA	NA	NA	NA	NA	NA	NA

The above details are taken from the Prospectus dated December 24, 2025, page number 115.

ii. Progress in the object(s):

Sr. No.	Item Head	Source of information/certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in ₹ Crore (A)	Amount utilized in ₹ Crore (B)			Total Unutilised amount in ₹ Crore as on 31 st March 2025 (C) A-B	Comments of the Monitoring Agency
				As at beginning of the quarter in ₹ Crore	During the quarter in ₹ Crore	At the end of the quarter in ₹ Crore		
1.	Proposed acquisition of Parekhs Hospital at Ahmedabad	Bank Statements, Company Letter, CA Certificate	77.00	0.00	77.00	77.00	0.00	Nil
2	Part-payment of purchase consideration for the already acquired "Ashwini Medical Centre"	Bank Statements, Company Letter, CA Certificate	12.40	0.00	12.40	12.40	0.00	Nil
3.	Acquisition of additional shareholding in our subsidiary namely "Harmony Medicare Private Limited" at Bharuch	Bank Statements, Company Letter, CA Certificate	10.78	0.00	10.78	10.78	0.00	Nil
4.	Funding of capital expenditure requirements of our Company towards setting up of a new hospital in Vadodara	Bank Statements, Company Letter, CA Certificate	30.09	0.00	4.95	4.95	25.14	Nil
5.	Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital at Vadodara location	Bank Statements, Company Letter, CA Certificate	6.83	0.00	0.00	0.00	6.83	Nil
6.	Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company	Bank Statements, Company Letter, CA Certificate	1.20	0.00	1.20	1.20	0.00	Nil
7.	Funding inorganic growth through unidentified acquisitions and General Corporate Purposes	Bank Statements, Company Letter, CA Certificate	87.44	50.04	24.78	74.82	12.62	Nil
8.	Issue Expenses	Bank Statements, Company Letter, CA Certificate	25.05	19.38	5.25	24.63	0.42	Nil
9.	Any other purpose approved by board	NA	NA	NA	NA	NA	NA	NA

The above details verified by CA certificate and Company Statement dated May 14, 2026.

iii. Deployment of unutilised issue proceeds:

Sr. No.	Type of instrument and name of entity invested in	Amount Invested (₹ Crore)	Maturity date	Earning (₹ Crore)	Return on Investment (%)	Market Value as at the end of the quarter
1	HDFC Bank – 57500001898251 (Public Issue Account)	4.95	-	-	-	-
2	HDFC Bank – 57500001898570 (Monitoring Account)	0.06	-	-	-	-
3	HDFC Bank – 50301281643451	10.0	20-07-2026		5.75	
4	HDFC Bank – 50301281644441	10.0	20-07-2026		5.75	
5	HDFC Bank – 50301281645187	10.0	20-07-2026		5.75	
6	HDFC Bank – 50301281646075	10.0	20-07-2026		5.75	

The above details verified by CA certificate and Company Statement date May 14, 2026.

iv. Delay in Implementation of Objects:

Object(s) Name	Completion Date		Delay	Comments of Board of Directors	
	As per Offer Document	Actual		No. of Days/ Months	Reason of Delay
Proposed acquisition of Parekhs Hospital at Ahmedabad	Up to Financial Year 2026-27	Completed	-	-	-
Part-payment of purchase consideration for the already acquired “Ashwini Medical Centre”	Up to Financial Year 2026-27	Completed	-	-	-
Acquisition of additional shareholding in our subsidiary namely “Harmony Medicare Private Limited” at Bharuch	Up to Financial Year 2026-27	Completed	-	-	-
Funding of capital expenditure requirements of our Company towards setting up of a new hospital in Vadodara	Up to Financial Year 2026-27	Ongoing	-	-	-
Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital at Vadodara location	Up to Financial Year 2026-27	Ongoing	-	-	-
Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company	Up to Financial Year 2026-27	Completed	-	-	-
Funding inorganic growth through unidentified acquisitions and General Corporate Purposes	Up to Financial Year 2026-27	Ongoing	-	-	-
Issue Expenses	Up to Financial Year 2026-27	Ongoing	-	-	-
Any other purpose approved by board	-	-	-	-	-

The above details are verified by Company Statement dated May 14, 2026.

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Item head	Amount in Rs. Crore (As on March 31,2026)	Remarks
General corporate purpose*	24.78	Nil

As per the prospectus dated December 24, 2025, the Company stated that it proposes to deploy the balance Net Proceeds towards general corporate purposes, subject to such amount not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations. The general corporate purposes for which the Company proposes to utilize Net Proceeds include funding organic and inorganic growth opportunities, including acquisitions, strengthening marketing capabilities and brand building exercises, meeting ongoing general corporate contingencies, business and operations, overheads, salaries & wages, administrative and general office use, finance costs, payment to Government and any other purpose as may be approved by the Board or a duly appointed committee from time to time, subject to compliance with applicable laws.

The above details are verified by CA certificate dated May 14, 2026.

Disclaimer

- a) This Report is prepared by **Brickwork Ratings India Private Limited** (hereinafter referred to as “**BWR**” or “**Monitoring Agency**” or “**MA**”). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal with any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013.
- e) While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- f) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.
- g) **BWR** is an independent Monitoring Agency and may determine, apply and amend its approach, processes and procedures in its sole discretion from time to time provided the same are in line with the SEBI ICDR Regulations.